Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting NR2F2
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Rectal, Vaginal, Transdermal, Intradermal, Intrathecal, Intratumoral, Intraperitoneal, Intra-arterial, Parenteral, Implant
01
Overview
siRNA targeting NR2F2 is a research-use-only small interfering RNA (siRNA) designed to knock down the expression of nuclear receptor subfamily 2 group F member 2 (NR2F2, also known as COUP-TFII). NR2F2 is an orphan nuclear receptor that plays critical roles in embryonic development, cell differentiation, angiogenesis, and epithelial-mesenchymal transition (EMT). In oncology research, NR2F2 knockdown via siRNA has been widely utilized to investigate its dual roles in tumor progression, metastasis, and drug resistance across various malignancies, including breast cancer, head and neck squamous cell carcinoma (HNSCC), lung adenocarcinoma, and colorectal cancer. Depending on the cellular context, silencing NR2F2 can either inhibit or promote cell proliferation and invasion, making it a valuable tool for dissecting the molecular pathways of tumorigenesis and identifying potential therapeutic targets.
- Other names
- COUP-TFII siRNANR2F2 RNAiNR-2F2 RNAiNR 2F2 RNAiNR2F2 siRNANR-2F2 siRNANR 2F2 siRNAsiRNA targeting COUP-TFII
02
Targets
NR2F2 (COUP-TFII / NR2F2)
Beyond the preview
Go deeper on siRNA targeting NR2F2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting NR2F2.